The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
26762835 |
342 |
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).![EBI](/images/logo_chembl.png) |
Icahn School of Medicine At Mount Sinai |
23920481 |
25 |
Synthesis and evaluation of heteroaryl substituted diazaspirocycles as scaffolds to probe the ATP-binding site of protein kinases.![EBI](/images/logo_chembl.png) |
The Institute of Cancer Research |
23394126 |
170 |
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).![EBI](/images/logo_chembl.png) |
Exelixis |
22726925 |
216 |
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.![EBI](/images/logo_chembl.png) |
Cellzome |
22404346 |
52 |
Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity.![EBI](/images/logo_chembl.png) |
The Institute of Cancer Research |
18183025 |
12060 |
A quantitative analysis of kinase inhibitor selectivity.![EBI](/images/logo_chembl.png) |
Ambit Biosciences |
17935989 |
146 |
Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.![EBI](/images/logo_chembl.png) |
Abbott Laboratories |
16876403 |
85 |
Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.![EBI](/images/logo_chembl.png) |
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories |
22056746 |
53 |
Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity.![EBI](/images/logo_chembl.png) |
Boehringer Ingelheim Pharmaceuticals |
21999461 |
90 |
1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.![EBI](/images/logo_chembl.png) |
RhôNe-Poulenc Rorer |
22037378 |
31824 |
Comprehensive analysis of kinase inhibitor selectivity.![EBI](/images/logo_chembl.png) |
Ambit Biosciences |
21300545 |
35 |
3,5-diarylazoles as novel and selective inhibitors of protein kinase D.![EBI](/images/logo_chembl.png) |
Novartis Institutes For Biomedical Research |
19654408 |
2521 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).![EBI](/images/logo_chembl.png) |
Ambit Biosciences |
20346655 |
117 |
Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.![EBI](/images/logo_chembl.png) |
Abbott Laboratories |
19926477 |
100 |
2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.![EBI](/images/logo_chembl.png) |
Abbott Laboratories |
32551607 |
52 |
Discovery of 4,6- and 5,7-Disubstituted Isoquinoline Derivatives as a Novel Class of Protein Kinase C ? Inhibitors with Fragment-Merging Strategy.![EBI](/images/logo_chembl.png) |
Asahi Kasei Pharma |
31757666 |
314 |
Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.![EBI](/images/logo_chembl.png) |
Merck |
30973735 |
91 |
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.![EBI](/images/logo_chembl.png) |
University of North Carolina At Chapel Hill |
31693351 |
473 |
Discovery of 4![EBI](/images/logo_chembl.png) |
TBA |
30384048 |
365 |
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.![EBI](/images/logo_chembl.png) |
University of Florida |
31526603 |
379 |
Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.![EBI](/images/logo_chembl.png) |
Takeda Pharmaceutical |
26509640 |
234 |
Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.![EBI](/images/logo_chembl.png) |
Abbvie Bioresearch Center |
30082069 |
359 |
ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.![EBI](/images/logo_chembl.png) |
Vertex Pharmaceuticals |
29945794 |
193 |
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.![EBI](/images/logo_chembl.png) |
Vertex Pharmaceuticals |
18829454 |
12 |
Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone.![BDB](/images/logo_bindingdb.png) |
University of Pittsburgh |
20444281 |
18 |
Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility.![BDB](/images/logo_bindingdb.png) |
University of Pittsburgh |